4932442K08Rik Inhibitors
Chemical inhibitors of 4932442K08Rik can effectively impede the protein's function through various mechanisms by targeting specific kinases and enzymes within its signaling pathways. Compounds like Wortmannin and LY294002 are known to inhibit phosphoinositide 3-kinases (PI3K), which play a crucial role in the Akt signaling pathway. Since 4932442K08Rik operates within this pathway, the inhibition of PI3K results in reduced activation of Akt, thus dampening the activity of 4932442K08Rik. Rapamycin, another inhibitor, exerts its effects by targeting mTOR, a kinase within the mTOR signaling pathway. By suppressing mTOR activity, Rapamycin indirectly leads to a decrease in 4932442K08Rik function, as mTOR is a critical component in the pathway that activates 4932442K08Rik.
Further inhibition is achieved through the use of PD98059, SB203580, and SP600125, which target kinases within the MAPK signaling pathways. PD98059 specifically inhibits MEK, thereby reducing ERK activation and subsequently downregulating 4932442K08Rik. SB203580 selectively inhibits p38 MAP kinase, which affects downstream components in the MAPK pathway including 4932442K08Rik. SP600125 impedes the function of JNK, another kinase in the MAPK pathways, which in turn leads to a decrease in the phosphorylation and activity of 4932442K08Rik. In addition, Src family kinases, which phosphorylate various substrates in multiple signaling pathways, can be inhibited by PP2 and Dasatinib, leading to a decreased functional activity of 4932442K08Rik. Erlotinib and Lapatinib, by targeting the tyrosine kinase activity of EGFR and HER2, respectively, lead to diminished downstream signaling that affects the function of 4932442K08Rik. Lastly, multi-targeted kinase inhibitors such as Sorafenib and Sunitinib, which inhibit a range of tyrosine protein kinases including RAF, PDGFR, and VEGFR, also serve to reduce the activity of 4932442K08Rik by disrupting the signaling cascades it is involved in.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K which is involved in the Akt signaling pathway. Since 4932442K08Rik is known to be part of this pathway, the inhibition of PI3K will lead to reduced phosphorylation and activation of Akt, thereby inhibiting the function of 4932442K08Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, a key kinase in the mTOR signaling pathway. Given that 4932442K08Rik is part of this pathway, inhibition of mTOR will lead to a decrease in 4932442K08Rik activity as downstream signaling is suppressed. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Targets and inhibits PI3K, which is upstream of Akt signaling. The inhibition of PI3K leads to a subsequent decrease in Akt activation, thus reducing the functional activity of 4932442K08Rik as part of this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which operates upstream of ERK in the MAPK signaling pathway. Since 4932442K08Rik is part of the MAPK pathway, inhibiting MEK would lead to reduced ERK activation and thus inhibit the function of 4932442K08Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Selectively inhibits p38 MAP kinase, which is involved in the MAPK signaling pathway. Inhibition of p38 MAPK results in the downregulation of downstream signaling components that include 4932442K08Rik, leading to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, part of the MAPK signaling pathways. By inhibiting JNK, the phosphorylation and activation of substrates involved in this pathway, including 4932442K08Rik, are decreased, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Inhibits Src family kinases. Src kinases can phosphorylate various substrates in different signaling pathways. By inhibiting Src kinases, the functional activity of 4932442K08Rik, which is a substrate in these pathways, is inhibited. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Targets and inhibits both HER2 and EGFR tyrosine kinases. Since 4932442K08Rik operates within the downstream signaling pathway of these kinases, inhibition by lapatinib will result in decreased functional activity of 4932442K08Rik. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple tyrosine protein kinases, including RAF kinases. The RAF/MEK/ERK pathway is one of the pathways in which 4932442K08Rik is involved, so inhibition of RAF leads to decreased 4932442K08Rik activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits Src family kinases as well as BCR-ABL and c-Kit. The inhibition of these kinases affects various signaling cascades including those in which 4932442K08Rik is a component, thus leading to the functional inhibition of 4932442K08Rik. | ||||||